Compound ID | 3397
Rhu-pGSN
Synonym(s): Rhu-plasma gelsolin
| Agent Type: | Indirect acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Activates phosphorylation of the lung bactericidal macrophage nitric oxide synthetase type III |
| Target Pathogen: | Active against Pseudomonas aeruginosa, Helicobacter pylori, and possibly Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecium, and Neisseria gonorrhoea; intended indication for community-acquired bacterial pneumonia, acute respiratory distress syndrome, and sepsis |
| Description: | Recombinant human plasma gelsolin |
| Institute where first reported: | BioAegis Therapeutics |
| Year first mentioned: | 2015 |
| Highest development stage: | Phase 2 |
| Development status: | Active |
| External links: | |
| Citation: | https://pmc.ncbi.nlm.nih.gov/articles/PMC4491512/ |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.